ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional ...
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
NEW YORK (Reuters Health) - Intravenous immunoglobulin (IVIg) may offer some relief for patients with sensorimotor neuropathy or nonataxic sensory neuropathy associated with primary Sjögren's syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results